More introductions for Collagen's Trilucent implant:
This article was originally published in Clinica
Executive Summary
Collagen (US) has launched its Trilucent breast implant in the Netherlands and Belgium. Since its introduction in the UK in September 1995, the soyabean oil filled implant has been launched in Germany, Spain, Austria and Switzerland. The company has also received US FDA approval to start a 400- patient trial of Trilucent at 30 US centres, and expects to commence trials within the next six months. Collagen hopes to submit an application for approval in two to four years.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.